WilmerHale Counsels Decibel Therapeutics in $55M Series C Financing

Download IconDownload Print IconPrint

WilmerHale Counsels Decibel Therapeutics in $55M Series C Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.

Decibel Therapeutics, Inc., a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, announced on June 19, 2018, the closing of a $55 million Series C financing. Proceeds from this funding round will be used to advance Decibel’s clinical and preclinical product candidates, as well as to build out the company’s comprehensive hearing drug discovery and development platform and capabilities.

The WilmerHale team representing Decibel was comprised of Lia Der Marderosian, Stephanie Singer and Jared Brenner.

Read Decibel’s press release about the financing.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel